MSD and Singapore. A Strategic Partnership for Long-Term Growth
Merck Sharp & Dohme healthcare in Singapore


Merck & Co., Inc., Whitehouse Station, New Jersey, USA (“Merck”) is a global healthcare leader that is committed to improving patients’ health and well-being through an innovative portfolio of medicines, vaccines, biologic therapies, consumer health and animal health products.

The US-based company has a history that dates back to 1851, and currently operates in more than 140 countries across the world.



Operating under the name of Merck Sharp & Dohme (MSD) outside the USA and Canada, the company established their first sales and marketing office in Singapore in 1993. Over the next decade, MSD expanded into manufacturing in Singapore, investing more than S$1 billion (US$0.77 billion) to establish two multi-product manufacturing facilities in its Tuas-based campus, and in 2007, MSD opened its Asia Pacific headquarters in Singapore.

Post merger with Schering-Plough, MSD’s manufacturing presence in Singapore doubled, and its operations extended into R&D, through the Translational Medicine Research Centre (TMRC), which supports MSD’s global R&D efforts through a range of preclinical and clinical development programs.


Today, MSD’s 1,500 employees in Singapore work across R&D, manufacturing and commercial operations to deliver the company’s medicines and therapies to patients in Asia and around the world. 

This breadth of operations in Singapore gives MSD a strategic presence in Asia and provides the opportunity for MSD to plan for a long-term, coordinated growth across its operations.

In 2011, MSD further signaled its intentions for the region by committing to additional investments in local research activities and manufacturing over ten years in Singapore as part of an agreement to expand its presence in Singapore. The agreement demonstrates MSD’s long-term vision for its operations across all facets of its business in Singapore.


Asia presents itself as a dynamic and fresh playing field for the biomedical sciences industry. With exponential growth of its market, companies seeking to succeed in the region need an in-depth understanding of local conditions and regulatory regimes.

With one of the fastest growing bio-clusters, Singapore plays an important role in helping companies expand in Asia. Through strategic partnership opportunities with a broad range of research institutes, corporate labs and public hospitals, companies will be  able to better understand and navigate the complexities in the region.

Singapore also attracts the world’s top scientific and business talents, with the Agency for Science, Technology and Research (A*STAR) offering scholarships to nurture local PhD graduates across the world’s top universities, making it easy for companies to tap into the talent potential in the region.

As a leading global manufacturing site for innovative medicines, Singapore is an ideal location for companies to develop new medicines for regional and global markets.

Visit the following link to understand more on pharmaceutical industry


"Merck's decision to relocate our Asia Pacific regional headquarters to Singapore is a bold testimony to our long-term confidence in and commitment to Singapore and the entire region." - Richard T. Clark, Chairman, President and CEO, Merck & Co.
About MSD

About MSD

Industry: Healthcare, Pharmacuaticals and Biotechnology
Headquarters: United States


The Deckbuilder helps you compile the content you want. Click “Add to deck” to collect useful content from the website and click on “View Deckbuilder” to edit and export your deck as a .ppt or .pdf file.